Free Trial

Abbott Laboratories (ABT) Competitors

$107.58
+3.31 (+3.17%)
(As of 06/7/2024 ET)

ABT vs. PFE, NVS, ISRG, SYK, AZN, VRTX, SNY, BSX, MDT, and BDX

Should you be buying Abbott Laboratories stock or one of its competitors? The main competitors of Abbott Laboratories include Pfizer (PFE), Novartis (NVS), Intuitive Surgical (ISRG), Stryker (SYK), AstraZeneca (AZN), Vertex Pharmaceuticals (VRTX), Sanofi (SNY), Boston Scientific (BSX), Medtronic (MDT), and Becton, Dickinson and Company (BDX). These companies are all part of the "medical" sector.

Abbott Laboratories vs.

Abbott Laboratories (NYSE:ABT) and Pfizer (NYSE:PFE) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, community ranking, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Abbott Laboratories has a net margin of 13.96% compared to Pfizer's net margin of -0.56%. Abbott Laboratories' return on equity of 20.18% beat Pfizer's return on equity.

Company Net Margins Return on Equity Return on Assets
Abbott Laboratories13.96% 20.18% 10.60%
Pfizer -0.56%8.64%3.70%

In the previous week, Pfizer had 17 more articles in the media than Abbott Laboratories. MarketBeat recorded 34 mentions for Pfizer and 17 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 0.96 beat Pfizer's score of 0.65 indicating that Abbott Laboratories is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abbott Laboratories
10 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pfizer
21 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
6 Negative mention(s)
1 Very Negative mention(s)
Positive

Abbott Laboratories presently has a consensus target price of $120.64, suggesting a potential upside of 12.14%. Pfizer has a consensus target price of $35.86, suggesting a potential upside of 25.46%. Given Pfizer's higher possible upside, analysts plainly believe Pfizer is more favorable than Abbott Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abbott Laboratories
0 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.70
Pfizer
0 Sell rating(s)
9 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.40

Abbott Laboratories has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Pfizer received 568 more outperform votes than Abbott Laboratories when rated by MarketBeat users. However, 69.67% of users gave Abbott Laboratories an outperform vote while only 69.06% of users gave Pfizer an outperform vote.

CompanyUnderperformOutperform
Abbott LaboratoriesOutperform Votes
921
69.67%
Underperform Votes
401
30.33%
PfizerOutperform Votes
1489
69.06%
Underperform Votes
667
30.94%

Abbott Laboratories has higher earnings, but lower revenue than Pfizer. Pfizer is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$40.11B4.67$5.72B$3.2133.51
Pfizer$58.50B2.77$2.12B-$0.06-476.25

Abbott Laboratories pays an annual dividend of $2.20 per share and has a dividend yield of 2.0%. Pfizer pays an annual dividend of $1.68 per share and has a dividend yield of 5.9%. Abbott Laboratories pays out 68.5% of its earnings in the form of a dividend. Pfizer pays out -2,799.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer is clearly the better dividend stock, given its higher yield and lower payout ratio.

75.2% of Abbott Laboratories shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 1.1% of Abbott Laboratories shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Abbott Laboratories beats Pfizer on 14 of the 20 factors compared between the two stocks.

Get Abbott Laboratories News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ABT vs. The Competition

MetricAbbott LaboratoriesPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$187.15B$6.97B$5.23B$17.71B
Dividend Yield2.11%2.66%2.73%3.55%
P/E Ratio33.5114.71131.3024.32
Price / Sales4.67243.992,422.4814.46
Price / Cash16.3932.9335.1620.21
Price / Book4.815.654.964.99
Net Income$5.72B$147.15M$110.48M$975.94M
7 Day Performance5.27%-2.06%-1.08%-1.87%
1 Month Performance2.52%-2.38%-0.68%-0.74%
1 Year Performance6.75%-5.74%2.88%8.66%

Abbott Laboratories Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PFE
Pfizer
4.6138 of 5 stars
$28.59
-0.7%
$35.86
+25.4%
-26.5%$162.01B$58.50B-476.4288,000
NVS
Novartis
2.2191 of 5 stars
$105.32
-0.8%
$116.67
+10.8%
+6.9%$215.27B$47.73B14.2176,057Positive News
ISRG
Intuitive Surgical
4.4497 of 5 stars
$417.61
-0.1%
$403.67
-3.3%
+35.9%$148.13B$7.12B75.3813,676Insider Selling
SYK
Stryker
4.5041 of 5 stars
$349.33
-0.1%
$370.58
+6.1%
+25.7%$133.08B$20.50B39.8852,000Positive News
AZN
AstraZeneca
2.5794 of 5 stars
$80.02
-1.0%
$88.00
+10.0%
+9.2%$248.10B$45.81B39.2389,900
VRTX
Vertex Pharmaceuticals
4.0967 of 5 stars
$483.04
-0.5%
$438.62
-9.2%
+48.8%$124.65B$9.87B31.355,400Analyst Downgrade
Analyst Revision
SNY
Sanofi
2.9115 of 5 stars
$48.98
-1.1%
$55.00
+12.3%
-3.7%$123.91B$46.61B24.6186,088Positive News
BSX
Boston Scientific
4.6343 of 5 stars
$77.12
+1.3%
$76.70
-0.6%
+52.1%$113.14B$14.24B64.8148,000Analyst Upgrade
Options Volume
MDT
Medtronic
4.7824 of 5 stars
$84.08
+2.1%
$93.00
+10.6%
+1.4%$111.64B$32.36B30.5795,000Analyst Forecast
BDX
Becton, Dickinson and Company
4.8181 of 5 stars
$240.63
+0.2%
$280.17
+16.4%
-4.6%$69.54B$19.37B53.0073,000Analyst Upgrade

Related Companies and Tools

This page (NYSE:ABT) was last updated on 6/8/2024 by MarketBeat.com Staff

From Our Partners